On Wednesday, Akero Therapeutics reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 78 the day before.
IBD's proprietary rating identifies price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating of over 80 as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Akero Therapeutics is not currently near a potential buying area. See if the stock goes on to build a base that could kick off a new climb.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
Akero Therapeutics holds the No. 132 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
